2017 Morgan Stanley Conference

Third quarter 2017 results and 2017 outlook Key elements from July 2017 Capital Markets Day

November 2017

Third quarter 2017 results and 2017 outlook

3Q'17 financial highlights

€2,019 m sales	 <i>÷</i> +9.8% up YoY <i>÷</i> +10.5% at constant scope and FX 	
	 +8% volume growth in High Performance Materials supported by successful innovation in major sustainability trends 	
€355 m EBITDA	 +17.2% up on 3Q'16 (€303 m) → Strong YoY growth in the three divisions 	
17.6% EBITDA margin	 ✤ 16.5% in 3Q'16 ✤ Margins up YoY in the three divisions 	
€158 m adjusted net income	 +43.6% up YoY +€2.08 adjusted EPS 	
€1,194 m net debt	 ÷ Excellent cash generation with a free cash flow at +€274 m ÷ Net debt significantly down versus 30 June 2017 (€1,471 m) ÷ Gearing down at 27% 	



Main announcements since 30 June 2017



Bostik

Acquisition of XL Brands

A leader in floor covering adhesives in the US

Enable Bostik to offer a full range of solutions in this growing market

US\$205 m EV, 11x EBITDA and 7x EBITDA within 4 to 5 years including synergies

Closing expected end 2017



Bostik

Opening of a new site in Gujarat, India

New manufacturing facility in addition to existing plant in Bangalore

Will serve the fast-growing demand for adhesives in industrial markets (flexible lamination, transportation and footwear)

For both India and export markets



Technical Polymers

+20% PVDF production capacity increase in North America

Will meet strong demand in water management, chemical process industry and high performance cables

Due to start mid-2018



4 2017 MORGAN STANLEY CONFERENCE

A very strong quarterly performance



ARKEMA

5 2017 MORGAN STANLEY CONFERENCE

3Q'17 key figures

In €m (except EPS)	3Q'16	3Q'17	CHANGE
Sales	1,838	2,019	+9.8%
EBITDA	303	355	+17.2%
EBITDA margin	16.5%	17.6%	
Recurring operating income (REBIT)	190	2 47	+30.0%
REBIT margin	10.3%	12.2%	
Adjusted net income	110	158	+43.6%
Net income – Group share	96	142	+47.9%
Adjusted EPS (in euros)	1.45	2.08	+43.4%



3Q'17 sales bridge





High Performance Materials (47% of Group sales)



* Volumes up +8.2% versus 3Q'16

- Very strong demand in Asia for lighter materials, batteries, photovoltaics, sports and consumer electronics
- Ramp-up of the new specialty molecular sieves unit in Honfleur (France)
- +7.9% sales impact from M&A reflecting Den Braven and CMP acquisitions and the divestment of the activated carbon and filter aid business

- Very good volume momentum in advanced materials (Technical Polymers + Performance Additives)
- Bostik expansion supported notably by Den Braven integration and first synergies
- * 16.9% EBITDA margin, slightly up YoY (16.7% in 3Q'16)

8 2017 MORGAN STANLEY CONFERENCE



Industrial Specialties (30% of Group sales)



\div Sales up +11.2% at constant scope of business and FX

- +11.5% price effect driven by good market conditions in Fluorogases and MMA/PMMA
- Overall stable volumes affected by the consequences of hurricane Harvey, particularly in Thiochemicals

- Confirmation of the return of Fluorogases to very good level of results, in line with the Group's expectations
- Continued tight market conditions in MMA/PMMA
- Overall solid performance in Thiochemicals
- \div 25.1% EBITDA margin, up YoY (22.2% in 3Q'16)





Coating Solutions (23% of Group sales)



3Q'17 highlights

- * Sales up +10.1% at constant FX and scope of business (divestment of oxo-alcohol business early March 2017)
 - +11.4 % price effect reflecting gradually improving acrylic cycle and actions to raise selling prices across the entire chain
 - Volumes impacted by the consequences of hurricane Harvey which offset the robust volume growth for coating resins

- In line with the Group's assumption, unit margins for acrylic monomers gradually improving from last year's low points
- Higher contribution from acrylic monomers more than offsetting the impact in downstream businesses of higher input costs
- * 13.4% EBITDA margin, up YoY (12.2% in 3Q'16)





Excellent cash flow in 3Q'17

In €m	3Q'17		
EBITDA	355		
Change in working capital ⁽¹⁾	94	Reflects tight control and usual seasonality of working capital	
Change in fixed assets payables (1)	4	• 15.5% working capital to annualized sales ratio versus 16.8% end of September 2016	
Current taxes	(50)		
Cost of debt	(24)		
Recurring capital expenditure (2)	(95)	• 2017e capex: slightly below the initial €450 m guidance	
Others	11		
RECURRING CASH FLOW	295		
Non-recurring items in operating and investing cash flow	(21)	Correspond mainly to the consequences of hurricane Harvey and restructuring costs	
FREE CASH FLOW	274		
Impact of portfolio management	(2)		
NET CASH FLOW	272		

(1) Excluding non-recurring items and impact of portfolio management

(2) Excluding exceptional capex and capex relating to portfolio management



2017 outlook

Focus on internal drivers

- Bostik expansion with the integration of Den Braven
- New high value-added applications in advanced materials notably related to major sustainability trends
- Limited improvement expected in 4Q versus last year in Fluorogases given this activity's seasonality
- Ongoing actions to reflect high costs of certain raw materials in the Group's selling prices
- Operational excellence initiatives to offset part of fixed costs inflation

In view of the above factors and the traditional seasonality of the Group's business towards the end of the year, and based on the results achieved in the first nine months of 2017, the Group now targets for the full year an EBITDA in the upper end of the €1,310 m to €1,350 m range announced in August.



Key elements from July 2017 Capital Markets Day

A strong track record...



14 2017 MORGAN STANLEY CONFERENCE

... including a significant step-up in financials





Significant achievements since last Capital Markets Day...



16 2017 MORGAN STANLEY CONFERENCE



Main levers of transformation

Organic growth

Innovation, partnerships and geographic expansion

Portfolio management

€3.7 bn sales acquired €2.2 bn sales divested

Productivity plans

Offset **1/2** to **2/3** of inflation on fixed costs

Lower capital intensity

5.6% of sales in 2016 versus **8%** at peak

Reduction of working capital

14.5% in 2016 versus **23%** in 2006





Arkema at a glance (2016)



18 2017 MORGAN STANLEY CONFERENCE

Our portfolio of businesses



19 2017 MORGAN STANLEY CONFERENCE

2016 sales by end markets



Diversity of end markets offers resilience and growth

20 2017 MORGAN STANLEY CONFERENCE

Leading positions on all key product lines

Rank	Business Lines	Main peers
#3	Bostik (adhesives and sealants)	Henkel, Sika, H.B. Fuller
#1	Specialty Polyamides	Evonik, Ems-Chemie, Ube
#1	PVDF (fluoropolymers)	Solvay, Kureha
#1	Sartomer (UV curing resins)	Allnex, Miwon
#1	Thiochemicals	Chevron Phillips
#2	MMA / PMMA	Mitsubishi Rayon, Evonik, Sumitomo
#3	Fluorogases	Honeywell, Chemours, Mexichem
#2	Acrylic Monomers	BASF, Dow, Nippon Shokubai
#3	Performance Coatings	BASF, Allnex, Dow
High Performance Materials	Industrial Specialties	 Coating Solutions
21 2017 MORGAN STANLEY CONFERENCE		ARKEMA



A global specialty chemical group strongly focused on adhesives and advanced materials, fostering customers innovation in megatrends and sustainability, and delivering best-in-class financial, operational and CSR performance.





Long-term financial objectives (2023)



Defined in normalized market conditions and under current IFRS rules

23 2017 MORGAN STANLEY CONFERENCE



Maintain disciplined capital allocation policy



With net debt to EBITDA < 2x



Our strategic priorities



25 2017 MORGAN STANLEY CONFERENCE

Accelerate growth of Advanced Materials and Adhesives



Reinforce footprint in higher growth countries



3 major growth pillars



Adhesives

Advanced Materials

Thiochemicals

28 2017 MORGAN STANLEY CONFERENCE

A wave of significant projects supporting our objectives



Planned calendar of these projects





Adhesives

Market
Fragmented market and ongoing consolidation by the leaders
Barriers to entry, resilience and low capital intensity
Substitution of mechanical fasteners by adhesives
Increasing needs for home efficiency and insulation

Arkema / Bostik

Participate in the consolidation of the market
Focused growth in core segments and high value niches
R&D efforts increased by 30% to foster innovation
Synergies with Arkema's Advanced Materials





Adhesives long-term ambition



- > Exceed **1/3** of Group sales
- > More than double sales versus 2016 in completing GDP+ organic growth by an ambitious bolt-on acquisition program
- > **12.5%** to **13%** REBIT margin
- > Maintain capex level below **3%** of sales



Advanced Materials





Advanced Materials long-term ambition



- > Exceed **25%** of Group sales
- > 14% to 15% REBIT margin
- > Support long-term growth of bio-based polyamide 11 with ~€300 m exceptional capex in Asia
- > R&D expenses at 4% of sales, up to 8% in certain applications





Targeting excellence is our driver

Commercial excellence

Accelerate our long-term growth

Program to be launched at the 2017 worldwide Senior Management convention

Key account management

Geographic expansion

End-market expertise

Place our customers at the heart of our digital strategy

Transversal innovation across businesses





A strong and balanced debt structure





36 2017 MORGAN STANLEY CONFERENCE



Dividend policy



A key element of shareholder return



DISCLAIMER

The information disclosed in this document may contain forward-looking statements with respect to the financial condition, results of operations, business and strategy of Arkema. Such statements are based on management's current views and assumptions that could ultimately prove inaccurate and are subject to material risk factors such as among others, changes in raw material prices, currency fluctuations, implementation pace of cost-reduction projects and changes in general economic and business conditions. These risk factors are further developed in the reference document.

Arkema does not assume any liability to update such forward-looking statements whether as a result of any new information or any unexpected event or otherwise.

Further information on factors which could affect Arkema's financial results is provided in the documents filed with the French Autorité des marchés financiers.

Financial information since 2005 is extracted from the consolidated financial statements of Arkema. Quarterly financial information is not audited.

The business segment information is presented in accordance with Arkema's internal reporting system used by the management.

The main performance indicators used by the Group are defined in the notes to the consolidated financial statements at 31 December 2016 included in section 4.3.3. of the 2016 Reference Document and in the press release. As part of the analysis of its results or to define its objectives, the Group also uses the following indicators:

REBIT margin: corresponds to the recurring operating income (REBIT) as a percentage of sales.

Free cash flow: corresponds to cash flow from operations and investments excluding the impact of portfolio management.

Exceptional capex: corresponds to exceptional investments which are unusual in size or nature.

EBITDA to free cash conversion: corresponds to the ratio of EBITDA on the free cash flow excluding exceptional capex. Free cash flow will be restated to offset the impact of the raw material environment on changes in working capital.

Return on capital employed: corresponds to the ratio of: (REBIT – current income taxes) / (net debt + shareholders' equity) under current IFRS rules.

